Edition:
United States

Hybrigenics SA (ALHYG.PA)

ALHYG.PA on Paris Stock Exchange

0.81EUR
24 Mar 2017
Change (% chg)

€0.01 (+1.25%)
Prev Close
€0.80
Open
€0.80
Day's High
€0.82
Day's Low
€0.80
Volume
45,444
Avg. Vol
152,410
52-wk High
€1.11
52-wk Low
€0.71

Latest Key Developments (Source: Significant Developments)

Hybrigenics FY revenue rises to 2.5 million euros
Monday, 13 Mar 2017 01:25pm EDT 

Hybrigenics SA : Cash position of 8.8 million euros as of Dec. 31, 2016 .FY revenue 2.5 million euros versus 1.2 million euros year ago.  Full Article

Hybrigenics announces results from Phase II study on inecalcitol
Thursday, 9 Feb 2017 12:37pm EST 

Hybrigenics SA : Announces encouraging preliminary results from the Phase II clinical study of inecalcitol in Chronic Myelogenous Leukemia . At this intermediate stage of study, 43 percent of the patients (6 out of 14) have shown further decrease in bcr-abl from mmr at three months . After one year of treatment, 33 percent (3 out of 9) have demonstrated reduction in BCR-ABL beyond DMR, i.e. undetectable biomarker traces .The sample size of this pilot study has been reduced to 42 patients, with a target completion in H2 2018.  Full Article

Hybrigenics H1 net loss widens to 2.9 million euros
Tuesday, 25 Oct 2016 01:08pm EDT 

Hybrigenics SA : H1 net loss 2.9 million euros ($3.16 million) versus loss of 2.3 million euros year ago . H1 operating loss of 2.9 million euros versus loss of 2.4 million euros year ago .H1 revenue from scientific services 1.7 million euros versus 1.5 million euros year ago.  Full Article

Hybrigenics gets FDA approval for inecalcitol phase II study
Monday, 11 Jan 2016 12:16pm EST 

Hybrigenics SA:Receives FDA approval for phase II clinical study of inecalcitol in acute myeloid leukemia in the United States.  Full Article

Hybrigenics gets authorization for clinical Phase II study of inecalcitol
Monday, 14 Dec 2015 11:47am EST 

Hybrigenics SA:Receives green light for a clinical Phase II double blind study against placebo of inecalcitol in acute myeloid leukemia.Authorization received from national agency for the security of medicines in France.  Full Article

Hybrigenics says Inecalcitol gets orphan drug designation
Sunday, 9 Aug 2015 08:00pm EDT 

Hybrigenics SA:Inecalcitol receives orphan drug designation for the treatment of acute myeloid leukemia in the United States.  Full Article

Hybrigenics appoints Alain Munoz chairman
Wednesday, 1 Jul 2015 12:58pm EDT 

Hybrigenics SA:Alain Munoz appointed chairman.  Full Article

Hybrigenics raises total of 9 million euros in capital increase
Tuesday, 7 Apr 2015 12:10pm EDT 

Hybrigenics SA:Raises total of 9 million euros in capital increase.6.5 million euros raised in a public offer.2.5 million euros raised in reserved capital increase.Price per share fixed at 1.41 euros.  Full Article

More From Around the Web

BRIEF-Hybrigenics FY revenue rises to 2.5 million euros

* FY revenue 2.5 million euros versus 1.2 million euros year ago Source text: http://bit.ly/2nx2WEu Further company coverage: (Gdynia Newsroom:)